Liraglutide (Victoza) vs Semaglutide (Ozempic)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Liraglutide (Victoza)
Marketed by Novo Nordisk
NCT00318461 · Phase 3 · completed
This was a large (n=1091), randomized, double-blind, parallel-group trial with both a placebo-controlled comparison (liraglutide + metformin vs metformin + liraglutide placebo) and an active-controlled comparison (glimepiride + metformin). The primary endpoint was change in HbA1c at week 26, a hard, regulator-accepted outcome for type 2 diabetes. The prespecified primary comparisons for liraglutide 1.2 mg and 1.8 mg/day were met: both were significantly superior to metformin alone (p<0.0001) and non-inferior to glimepiride + metformin within the 0.4% margin. The 0.6 mg dose was superior to metformin but did not meet non-inferiority against glimepiride + metformin, which does not negate the positive results for the clinically relevant doses.
Next expected readout: June 2027 · NCT03883412 (registry estimate)
Reported efficacy
Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26); Change in Glycosylated A1c (HbA1c) at Week 104 (week 0, week 104): Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00318461
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)
Result source: NCT03819153
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Liraglutide (Victoza) | Semaglutide (Ozempic) |
|---|---|---|
| HbA1c, change | -0.6% vs 0.4%−1.1 vs placeboNCT0154121527 other results
| -1.6% vs 0%−1.6 vs placeboNCT0205489735 other results
|
| Body weight, change (kg) | -2.3 vs 1.0−3.3 vs placeboNCT0154121522 other results
| -4.9 vs -0.6−4.3 vs placeboNCT0172044632 other results
|
| HbA1c below 7% | 63.7% vs 36.5%+27.2 vs placeboNCT015412153 other results
| 72.3% vs 24.8%+47.5 vs placeboNCT0205489710 other results
|
| Fasting plasma glucose, change | -1.6 vs 1.0−2.6 vs placeboNCT0154121521 other results
| -2.1 vs -0.9−1.2 vs placeboNCT0172044624 other results
|
| 3-point MACE (% with event) | 13% vs 14.9%−1.9 vs placeboNCT01179048 | 6.6% vs 8.9%−2.3 vs placeboNCT017204461 other result
|
HbA1c, change
- Liraglutide (Victoza)
- -0.6% vs 0.4%−1.1 vs placeboNCT01541215
27 other results
- -0.6% vs -0.5% NCT00318461
- -1% vs -1.0% NCT00318461
- -0.6% vs -0.5% NCT00318461
- -1.0% vs -1.0% NCT00318461
- -0.4% vs -0.5% NCT00318461
- -0.7% vs -1.0% NCT00318461
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -1.7% vs -1.2% NCT03172494
- -1.2% vs -1.2% NCT03172494
- -1.9% vs -1.1% NCT03175120
- -1.9% vs -0.7% NCT02911948
- -1.5% vs -1.5% NCT02420262
- -1.8% vs -1.1% NCT01952145
- -0.7% vs 0.7% NCT01541215
- -2.4% vs -1.8% NCT02607306
- -1.8% vs -1.8% NCT02607306
- -2.0% vs -1.7% NCT02501161
- 7.9% vs 8.9% NCT01505673
- 6.4% vs 6.4% NCT02765399
- -1.1% vs -0.5% NCT01907854
- -1.8% vs -1.2% NCT01973231
- -1.7% vs -1.0% NCT02008682
- 4.1% vs 3.4% NCT01966978
- -1.4% vs -1.1% NCT02730377
- -1.3% vs -0.7% NCT01917656
- -1.1% vs 0.2% NCT00318422
- Semaglutide (Ozempic)
- -1.6% vs 0%−1.6 vs placeboNCT02054897
35 other results
- -1.9% vs -0.1% NCT02305381
- -1.6% vs -0.2% NCT03086330
- -1.5% vs 0% NCT02054897
- -1.4% vs -0.1% NCT02305381
- -1.5% vs -0.9% NCT01885208
- -1.6% vs -0.6% NCT01930188
- -1.8% vs -1.1% NCT02648204
- -1.6% vs -0.8% NCT02128932
- -1.7% vs -1.1% NCT03191396
- -1.3% vs -0.6% NCT01930188
- -1.5% vs -1.1% NCT02648204
- -1.2% vs -0.8% NCT02128932
- -1.5% vs -1.2% NCT03689374
- -1.4% vs -0.7% NCT05514535
- -1.4% vs -0.4% NCT01720446
- -1.1% vs -0.4% NCT01720446
- -0.9% vs -0.0% NCT03819153
- -1.8% vs -0.3% NCT05649137
- -0.8% vs 0.2% NCT04560998
- -2.0% vs -0.7% NCT02207374
- -2.2% vs -0.7% NCT02254291
- -1.7% vs -0.7% NCT02207374
- -1.9% vs -0.7% NCT02254291
- -1.4% vs -0.7% NCT05514535
- -1.9% vs -1.1% NCT05486065
- -1.1% vs -0.4% NCT05144984
- -2.1% vs -1.1% NCT05486065
- -1.8% vs -1.1% NCT05486065
- -2.3% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.3% vs -0.4% NCT05144984
- -0.5% vs 0% NCT04538352
- -1.4% vs -1.0% NCT03596450
- -1.5% vs -1.1% NCT03596450
Body weight, change (kg)
- Liraglutide (Victoza)
- -2.3 vs 1.0−3.3 vs placeboNCT01541215
22 other results
- -2.5 vs -0.9 NCT01541215
- -2.9 vs 0.7 NCT00318461
- -2.8 vs 0.9 NCT00318461
- -3.0 vs 0.7 NCT00318461
- -2.6 vs 0.9 NCT00318461
- -2.1 vs 0.7 NCT00318461
- -1.8 vs 0.9 NCT00318461
- 1.2 vs 3 NCT02501161
- 2.9 vs 4.1 NCT02607306
- -1 vs 4.1 NCT02607306
- 0.2 vs 1.3 NCT03172494
- -2.5 vs 1.3 NCT03172494
- -0.7 vs 0.5 NCT03175120
- 0.5 vs 2.2 NCT02501161
- -0.7 vs 0.7 NCT02911948
- -0.9 vs 2.6 NCT02420262
- -1.4 vs 1.8 NCT01952145
- -3.8 vs -3.5 NCT02730377
- -3.3 vs -1.8 NCT01907854
- -4.2 vs -3.7 NCT01973231
- -5.4 vs -1.5 NCT01917656
- -0.6 vs 3.1 NCT01966978
- Semaglutide (Ozempic)
- -4.9 vs -0.6−4.3 vs placeboNCT01720446
32 other results
- -3.6 vs -0.6 NCT01720446
- -5.5 vs -1.4 NCT03819153
- -4.7 vs -0.9 NCT02054897
- -6.4 vs -1.4 NCT02305381
- -4.7 vs -1 NCT03086330
- -3.7 vs -0.9 NCT02054897
- -3.7 vs -1.4 NCT02305381
- -14.9 vs -4.6 NCT05649137
- -5.2 vs -1.2 NCT04560998
- -5.6 vs -1.9 NCT01885208
- -6.1 vs -1.9 NCT01930188
- -6.5 vs -2.3 NCT02648204
- -5.2 vs 1.1 NCT02128932
- -5.8 vs -2 NCT03191396
- -4.3 vs -1.9 NCT01930188
- -3.5 vs 1.1 NCT02128932
- -4.2 vs 2.9 NCT03689374
- -4.2 vs -0.4 NCT03061214
- -4.6 vs -2.3 NCT02648204
- -3 vs -0.4 NCT03061214
- -5.7 vs -4.3 NCT03136484
- -8.0 vs 0.4 NCT05514535
- -8.9 vs -2.3 NCT05486065
- -4.7 vs -2.6 NCT05144984
- -13.1 vs -2.3 NCT05486065
- -10.1 vs -2.3 NCT05486065
- -8.9 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -10 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -5 vs -3.1 NCT03596450
- -8.6 vs 1.4 NCT04538352
HbA1c below 7%
- Liraglutide (Victoza)
- 63.7% vs 36.5%+27.2 vs placeboNCT01541215
3 other results
- 51.8% vs 23.2% NCT02964247
- 76.5% vs 52.6% NCT02008682
- 44% vs 20% NCT01966978
- Semaglutide (Ozempic)
- 72.3% vs 24.8%+47.5 vs placeboNCT02054897
10 other results
- 78.6% vs 10.5% NCT02305381
- 82.5% vs 20.5% NCT03086330
- 74.2% vs 24.8% NCT02054897
- 60.6% vs 10.5% NCT02305381
- 78.7% vs 52.2% NCT02648204
- 84% vs 49.6% NCT03061214
- 80.4% vs 45.9% NCT03191396
- 68.4% vs 52.2% NCT02648204
- 74.5% vs 49.6% NCT03061214
- 76.1% vs 50.8% NCT03136484
Fasting plasma glucose, change
- Liraglutide (Victoza)
- -1.6 vs 1.0−2.6 vs placeboNCT01541215
21 other results
- -1.1 vs 0.8 NCT01541215
- -1.2 vs -0.6 NCT00318461
- -1.7 vs -1.3 NCT00318461
- -1.2 vs -0.6 NCT00318461
- -1.6 vs -1.3 NCT00318461
- -0.8 vs -0.6 NCT00318461
- -1.1 vs -1.3 NCT00318461
- -3.9 vs -3.7 NCT02501161
- -4.1 vs -4.0 NCT02607306
- -2.6 vs -4.0 NCT02607306
- -3.6 vs -3.5 NCT03172494
- -1.9 vs -3.5 NCT03172494
- -3.6 vs -2.8 NCT03175120
- -4.0 vs -3.8 NCT02501161
- -2.8 vs -2.3 NCT02911948
- 6.4 vs 6.4 NCT02765399
- -2.2 vs -1.2 NCT02730377
- -2.9 vs -1.6 NCT01973231
- -2.3 vs -1.2 NCT02008682
- -0.1 vs 0.1 NCT01917656
- -1.8 vs -0.6 NCT01917656
- Semaglutide (Ozempic)
- -2.1 vs -0.9−1.2 vs placeboNCT01720446
24 other results
- -1.8 vs -0.9 NCT01720446
- -2.4 vs -0.6 NCT02054897
- -2.4 vs -0.5 NCT02305381
- -2.3 vs 0.1 NCT03086330
- -2.4 vs -0.6 NCT02054897
- -1.6 vs -0.5 NCT02305381
- -3.3 vs -1.1 NCT05649137
- -2.8 vs -2 NCT01885208
- -2.6 vs -1.1 NCT01930188
- -2.8 vs -1.9 NCT02648204
- -2.7 vs -2.1 NCT02128932
- -2.6 vs -1 NCT03061214
- -2.6 vs -1.5 NCT03191396
- -2.1 vs -1.1 NCT01930188
- -2.2 vs -1.9 NCT02648204
- -2.0 vs -2.1 NCT02128932
- -1.3 vs -0.8 NCT03689374
- -2.2 vs -1 NCT03061214
- -2.5 vs -2 NCT03136484
- -1.4 vs -0.1 NCT05144984
- -3.9 vs -0.1 NCT05144984
- -3.4 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
3-point MACE (% with event)
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- Semaglutide (Ozempic)
- 6.6% vs 8.9%−2.3 vs placeboNCT01720446
1 other result
- 12% vs 14.4% NCT03819153
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
23 other shared endpoints and safety
Coverage. Liraglutide (Victoza): 27 of 27 rows · Semaglutide (Ozempic): 27 of 27 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Victoza) Rows use multiple source trials | Semaglutide (Ozempic) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -1.3 vs -1.2 Oral Antidiabetic Drug kg @ 104wk1.8 mga,b,c,d NCT02730377 · Phase 4 · registry result, not featured evidence | -5.3 vs -1.6 placebo kg @ 72wk7.2 mga,b,c,d NCT05649137 · Phase 3 · registry result, not featured evidence |
| DBP absolute change · mmHg | -0.72 vs -1.12 placebo mmHg @ 26wkb,c,e NCT02964247 · Phase 3 · registry result, not featured evidence | -0.4 vs -0.8 placebo mmHg @ 104wkb,c,e NCT03819153 · Phase 3 1 other source trial-1.9 vs -1.4 Standard of Care mmHg @ 104wk NCT03596450 · Phase 4 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.02% (n=200) @ 32wkf,g,c,h NCT02298192 · Phase 3 · registry result, not featured evidence show 1 more dose-2.01% (n=189) @ 32wk NCT02298192 · Phase 3 · registry result, not featured evidence | -1.23% (n=91) @ 52wkg,c,h NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-0.86% (n=335) @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| HbA1c Decrease 1 0 responder rate · % of participants | 52.31% (n=195) vs 16.84% (n=95) placebo @ 26wkg,c,i Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 76.5% (n=293) vs 48.6% (n=313) Canagliflozin @ 52wkg,c,i Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain responder rate · % of participants | 47.69% (n=195) vs 19.15% (n=94) placebo @ 26wkg,c,i Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 69.6% (n=293) vs 45% (n=313) Canagliflozin @ 52wkg,c,i Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain event count · % of participants | 13.7% (n=270) vs 8.3% (n=265) Insulin Degludec @ 52wk*f,j,g,c NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 37 Participants as posted show 1 more dose52% (n=271) vs 8.3% (n=265) Insulin Degludec @ 52wk* NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 141 Participants as posted | 48.5% (n=410) vs 37.3% (n=426) Standard of Care @ 52wk*j,g,c Yes NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 199 Participants as posted |
| HbA1c Less Than 7% event count · % of participants | 48.2% (n=56) vs 30.8% (n=52) placebo @ 52wk*1.8 mgj,g,c Yes NCT01541215 · Phase 3 · converted to % from 27 Participants as posted 2 other source trials89.1% (n=275) vs 69.7% (n=271) Insulin Degludec @ 52wk* Yes NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 245 Participants as posted 76.2% (n=273) vs 69.7% (n=271) Insulin Degludec @ 52wk* Yes NCT02607306 · Phase 3 · registry result, not featured evidence · converted to % from 208 Participants as posted | 56.7% (n=430) vs 48.9% (n=462) Standard of Care @ 52wk*j,g,c Yes NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 244 Participants as posted |
| HbA1c Less Than 7% event count · % of participants No placebo or comparator arm | 89.5% (n=200) @ 32wk*f,j,g,c,k NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 179 participants as posted show 1 more dose89.9% (n=189) @ 32wk* NCT02298192 · Phase 3 · registry result, not featured evidence · converted to % from 170 participants as posted | 56.5% (n=92) @ 24wk*j,g,c,k Yes NCT05533632 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted |
| HbA1c Less Than or Equal to 6.5 event count · % of participants | 44.6% (n=56) vs 25% (n=52) placebo @ 52wk*1.8 mgl,m,c,n Yes NCT01541215 · Phase 3 · converted to % from 25 Participants as posted | 72.6% (n=288) vs 16% (n=94) placebo @ 72wk*7.2 mgl,m,c,n NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 209 Participants as posted |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 61.7% (n=162) vs 26.3% (n=175) Sitagliptin @ 26wkl,a,g,c,i NCT02008682 · Phase 4 · registry result, not featured evidence 1 other source trial34.36% (n=195) vs 9.47% (n=95) placebo @ 26wk Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 62.1% (n=293) vs 26.8% (n=313) Canagliflozin @ 52wkl,a,g,c,i Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c Reduction 1% and Weight Loss 3% responder rate · % of participants | 29.74% (n=195) vs 7.45% (n=94) placebo @ 26wkg,c,i Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 57.3% (n=293) vs 34.8% (n=313) Canagliflozin @ 52wkg,c,i Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| HDL Cholesterol ratio to baseline · ratio | 1.01 vs 1.02 Insulin Degludec ratio @ 26wkf,b,c,i NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose1.03 vs 1.02 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 1.04 vs 0.99 placebo ratio @ 52wkb,c,i NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials1 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 1.04 vs 1.08 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| Hypoglycemia Episodes Level 2 or 3 event count · count | 38 vs 36 Insulin Degludec count @ 26wkb,c,o NCT03175120 · Phase 3 · registry result, not featured evidence | 22 vs 46 Insuline Glargine U100 (Titrated) count @ 40wkb,c,o NCT05514535 · Phase 3 · registry result, not featured evidence · combination 2 other source trials3 vs 3 Dulaglutide count0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 7 vs 3 Dulaglutide count1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence |
| LDL Cholesterol ratio to baseline · ratio | 0.92 vs 1.01 Insulin Degludec ratio @ 26wkf,b,c,i NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.96 vs 1.01 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.99 vs 1.03 placebo ratio @ 52wkb,c,i NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials1 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 0.96 vs 1.05 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| PPG Excursion absolute change · mmol/L | -0.747 vs -0.397 placebo mmol/L @ 52wk1.8 mgg,c NCT01541215 · Phase 3 2 other source trials-0.74 vs -0.27 Insulin Degludec mmol/L @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence -1.01 vs -0.27 Insulin Degludec mmol/L @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence | -0.7 vs -0.9 Insulin Aspart mmol/L @ 52wkg,c NCT03689374 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -1.95 vs -3.35 placebo mmHg @ 26wkb,c,e NCT02964247 · Phase 3 · registry result, not featured evidence | -3.9 vs -1.4 placebo mmHg @ 104wkb,c,e NCT03819153 · Phase 3 1 other source trial-3 vs -2.8 Standard of Care mmHg @ 104wk NCT03596450 · Phase 4 · registry result, not featured evidence |
| SMBG 7-point absolute change · mmol/L | -2.309 vs -0.748 placebo mmol/L @ 52wk1.8 mgg,c NCT01541215 · Phase 3 | -2.1 vs -2.1 Insulin Aspart mmol/L @ 52wkg,c NCT03689374 · Phase 3 · registry result, not featured evidence 1 other source trial-2.8 vs -1.9 Canagliflozin mmol/L @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| Total Cholesterol ratio to baseline · ratio | 0.94 vs 0.99 Insulin Degludec ratio @ 26wkf,b,c,i NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.97 vs 0.99 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.96 vs 1 placebo ratio @ 52wkb,c,i NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials1 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 0.96 vs 1.03 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| Triglyceride ratio to baseline · ratio | 0.88 vs 0.82 Insulin Degludec ratio @ 26wkf,b,c,i NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.9 vs 0.82 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.8 vs 0.95 placebo ratio @ 52wkb,c,i NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials0.9 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 0.86 vs 0.92 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| VLDL Cholesterol ratio to baseline · ratio | 0.9 vs 0.84 Insulin Degludec ratio @ 26wkf,p,g,q NCT03172494 · Phase 3 · registry result, not featured evidence show 1 more dose0.92 vs 0.84 Insulin Degludec ratio @ 26wk NCT03172494 · Phase 3 · registry result, not featured evidence | 0.95 vs 0.86 placebo ratio @ 34wk21.6 mgf,p,g,q NCT05144984 · Phase 2 · registry result, not featured evidence show 4 more doses0.72 vs 0.86 placebo ratio @ 34wk2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 0.75 vs 0.86 placebo ratio @ 34wk2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 0.78 vs 0.86 placebo ratio @ 34wk2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 0.76 vs 0.86 placebo ratio @ 34wk2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Waist Circumference Change absolute change · cm | 2.5 vs 3.4 Insulin Degludec cm @ 52wkf,g,c NCT02607306 · Phase 3 · registry result, not featured evidence show 1 more dose-1.1 vs 3.4 Insulin Degludec cm @ 52wk NCT02607306 · Phase 3 · registry result, not featured evidence | -3.3 vs 2.1 Insulin Aspart cm @ 52wkg,c NCT03689374 · Phase 3 · registry result, not featured evidence 1 other source trial-4.2 vs -3 Canagliflozin cm @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| Weight percent change · % of baseline | -7.2% (n=35) vs -3.1% (n=37) placebo @ 84wkj,g,c,r NCT01234649 · Phase 3 · registry result, not featured evidence · combination | -4.47% (n=389) vs -2.68% (n=386) Standard of Care @ 104wkj,g,c,r NCT03596450 · Phase 4 · registry result, not featured evidence |
| Weight Loss 3% responder rate · % of participants | 46.43% (n=196) vs 41.24% (n=97) placebo @ 26wkg,c,i Yes NCT02964247 · Phase 3 · registry result, not featured evidence | 68.8% (n=298) vs 64.9% (n=313) Canagliflozin @ 52wkg,c,i Yes NCT03136484 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 21.1%1.8 mg dailys NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results18.3%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 3% NCT01179048 · Phase 3 15.2%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 41.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 55.2%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 6.3% NCT02765399 · Phase 4 · registry result, not featured evidence 22% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 10.9% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 8.6% NCT01505673 · Phase 4 · registry result, not featured evidence 7.9% NCT01907854 · Phase 4 · registry result, not featured evidence 5.4% NCT01973231 · Phase 4 · registry result, not featured evidence 14.7% NCT02008682 · Phase 4 · registry result, not featured evidence 15.1% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 5.5%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 16.1%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 55.1% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4% NCT03175120 · Phase 3 · registry result, not featured evidence 4.3% NCT02501161 · Phase 3 · registry result, not featured evidence 1.5% NCT02964247 · Phase 3 · registry result, not featured evidence 7.6%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 3.7%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 0% NCT02911948 · Phase 3 · registry result, not featured evidence 4.8% NCT02773368 · Phase 3 · registry result, not featured evidence 0.8% NCT02420262 · Phase 3 · registry result, not featured evidence 2.9%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 10.1% NCT01952145 · Phase 3 · registry result, not featured evidence | 1.3%1.0 mgt NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results1.7%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.4% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 7.8%0.5 mg weekly NCT02054897 · Phase 3 5.1%1.0 mg weekly NCT01930188 · Phase 3 · combination 5.4%0.5 mg weekly NCT01930188 · Phase 3 · combination 5.3%1.0 mg/week NCT02128932 · Phase 3 7.5%0.5 mg/week NCT02128932 · Phase 3 3.8%2.0 mg weekly NCT03989232 · Phase 3 2.1%1.0 mg weekly NCT03989232 · Phase 3 3.8%1.0 mg weekly NCT02305381 · Phase 3 3.8%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 10.6% NCT05533632 · Phase 4 · registry result, not featured evidence 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 28.1% NCT03596450 · Phase 4 · registry result, not featured evidence 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination 1.7%Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 3.9%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 18.3%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 7.6% NCT04560998 · Phase 3 · registry result, not featured evidence 1.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence 9.7%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 8.7%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.9% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 2.6%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 7.3%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 4.1%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.5%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.9%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 8.2%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 11.3%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 12.9%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 3.9%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.7%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 12%1.8 mg dailys NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.5%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.5%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT01179048 · Phase 3 0%1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 —1.8 mg NCT01541215 · Phase 3 — NCT03260881 · Phase 4 · registry result, not featured evidence 7.4% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 7.9%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence — NCT02765399 · Phase 4 · registry result, not featured evidence — NCT01966978 · Phase 4 · registry result, not featured evidence · combination — NCT02014740 · Phase 4 · registry result, not featured evidence — NCT02299388 · Phase 4 · registry result, not featured evidence — NCT01505673 · Phase 4 · registry result, not featured evidence — NCT01907854 · Phase 4 · registry result, not featured evidence — NCT01973231 · Phase 4 · registry result, not featured evidence — NCT02008682 · Phase 4 · registry result, not featured evidence 6.4% NCT01917656 · Phase 4 · registry result, not featured evidence · combination — NCT02889510 · Phase 3 · registry result, not featured evidence 1.4%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 8.3%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence — NCT01234649 · Phase 3 · registry result, not featured evidence · combination 0.7% NCT03175120 · Phase 3 · registry result, not featured evidence 0.4% NCT02501161 · Phase 3 · registry result, not featured evidence — NCT02964247 · Phase 3 · registry result, not featured evidence 2.9%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.2%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence — NCT02911948 · Phase 3 · registry result, not featured evidence — NCT02773368 · Phase 3 · registry result, not featured evidence 0.4% NCT02420262 · Phase 3 · registry result, not featured evidence 1%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 2.9%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence — NCT01937598 · Phase 3 · registry result, not featured evidence 3.2% NCT01952145 · Phase 3 · registry result, not featured evidence | —1.0 mgt NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results—0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT03819153 · Phase 3 —1.0 mg weekly NCT02054897 · Phase 3 —0.5 mg weekly NCT02054897 · Phase 3 —1.0 mg weekly NCT01930188 · Phase 3 · combination —0.5 mg weekly NCT01930188 · Phase 3 · combination —1.0 mg/week NCT02128932 · Phase 3 —0.5 mg/week NCT02128932 · Phase 3 —2.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT02305381 · Phase 3 —0.5 mg weekly NCT02305381 · Phase 3 — NCT04126603 · Phase 4 · registry result, not featured evidence — NCT05786521 · Phase 4 · registry result, not featured evidence 3.8% NCT05533632 · Phase 4 · registry result, not featured evidence —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 2.2% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination —7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence —1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence — NCT04560998 · Phase 3 · registry result, not featured evidence — NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence —0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence — NCT03136484 · Phase 3 · registry result, not featured evidence · combination —1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 0%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence —2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence —2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 6.6%1.8 mg dailys NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results10.4%1.2 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%0.6 mg daily NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 49.7% NCT01179048 · Phase 3 13.6%1.8 mg NCT01541215 · Phase 3 13.5%1.8 mg NCT01541215 · Phase 3 4.2%1.8 mg NCT01541215 · Phase 3 0% NCT03260881 · Phase 4 · registry result, not featured evidence 38.2% NCT01919489 · Phase 4 · registry result, not featured evidence · combination 9.4%1.8 mg NCT02730377 · Phase 4 · registry result, not featured evidence 0% NCT02765399 · Phase 4 · registry result, not featured evidence 11.1% NCT01966978 · Phase 4 · registry result, not featured evidence · combination 0% NCT02014740 · Phase 4 · registry result, not featured evidence 0% NCT02299388 · Phase 4 · registry result, not featured evidence 2.9% NCT01505673 · Phase 4 · registry result, not featured evidence 3% NCT01907854 · Phase 4 · registry result, not featured evidence 5.9% NCT01973231 · Phase 4 · registry result, not featured evidence 1.6% NCT02008682 · Phase 4 · registry result, not featured evidence 1.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination 0% NCT02889510 · Phase 3 · registry result, not featured evidence 3.9%Insulin Degludec/Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 7.8%Liraglutide NCT03172494 · Phase 3 · registry result, not featured evidence 0% NCT01234649 · Phase 3 · registry result, not featured evidence · combination 4.3% NCT03175120 · Phase 3 · registry result, not featured evidence 11.9% NCT02501161 · Phase 3 · registry result, not featured evidence 2.5% NCT02964247 · Phase 3 · registry result, not featured evidence 6.2%Insulin Degludec/Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 5.1%Liraglutide NCT02607306 · Phase 3 · registry result, not featured evidence 2.9% NCT02911948 · Phase 3 · registry result, not featured evidence 2.9% NCT02773368 · Phase 3 · registry result, not featured evidence 4.8% NCT02420262 · Phase 3 · registry result, not featured evidence 6.7%IDegLira NCT02298192 · Phase 3 · registry result, not featured evidence 3.3%IDegLira (1WT) NCT02298192 · Phase 3 · registry result, not featured evidence 0% NCT01937598 · Phase 3 · registry result, not featured evidence 1.8% NCT01952145 · Phase 3 · registry result, not featured evidence | 33.6%1.0 mgt NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results35%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 9.4%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 49.6% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 5.5%0.5 mg weekly NCT02054897 · Phase 3 7.3%1.0 mg weekly NCT01930188 · Phase 3 · combination 7.3%0.5 mg weekly NCT01930188 · Phase 3 · combination 4.7%1.0 mg/week NCT02128932 · Phase 3 6.1%0.5 mg/week NCT02128932 · Phase 3 4.4%2.0 mg weekly NCT03989232 · Phase 3 5.2%1.0 mg weekly NCT03989232 · Phase 3 9.2%1.0 mg weekly NCT02305381 · Phase 3 6.1%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 1% NCT05533632 · Phase 4 · registry result, not featured evidence 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 6% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 5.9%INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 9.8%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 19.7%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 18.7% NCT04560998 · Phase 3 · registry result, not featured evidence 6.2% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 7.4% NCT03689374 · Phase 3 · registry result, not featured evidence 6.6%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.3%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 4.6% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 5.9%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 4.7%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7.7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5.6%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 7.9%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 5.8%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 6.7%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 1.6%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.3%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 2.6%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 7.8%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 6.5%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 4.1%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 1.8 mg dailys nausea 21.5% diarrhoea 16.5% nasopharyngitis 14.9% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 32 more results1.2 mg daily nausea 17.5% nasopharyngitis 15% headache 14.2% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6 mg daily nasopharyngitis 17.8% diarrhoea 12.8% nausea 12.4% NCT00318461 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.8 mg nausea 28.8% (placebo 13.2%) vomiting 25.8% (placebo 8.8%) diarrhoea 22.7% (placebo 16.2%) NCT01541215 · Phase 3 1.8 mg nasopharyngitis 3.8% (placebo 27.9%) vomiting 3.8% (placebo 8.8%) abdominal pain 1.9% (placebo 7.4%) NCT01541215 · Phase 3 1.8 mg hyperglycaemia 2.1% (placebo 5.9%) pharyngitis 2.1% (placebo 5.9%) abdominal pain 0% (placebo 7.4%) NCT01541215 · Phase 3 abdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence nausea 25% (placebo 14.3%) NCT02765399 · Phase 4 · registry result, not featured evidence gi 77.8% headache 25.9% other ae 7.4% NCT01966978 · Phase 4 · registry result, not featured evidence · combination nausea 29.1% NCT02014740 · Phase 4 · registry result, not featured evidence nausea 31.4% (placebo 19.4%) decreased in apetite 17.1% (placebo 11.1%) diarrhea 11.4% (placebo 8.3%) NCT01505673 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 16.3% decreased appetite 8.9% NCT01907854 · Phase 4 · registry result, not featured evidence nausea 21.8% diarrhoea 12.4% lipase increased 8.4% NCT01973231 · Phase 4 · registry result, not featured evidence nausea 14.8% decreased appetite 10.9% diarrhoea 8.2% NCT02008682 · Phase 4 · registry result, not featured evidence vomiting 5.3% NCT01917656 · Phase 4 · registry result, not featured evidence · combination gastrointestinal disorders 27.1% (placebo 5.7%) general disorders and administration site conditions 2.9% (placebo 0%) nervous system disorders 2.9% (placebo 2.9%) NCT02889510 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18.4% diabetic retinopathy 7.8% lipase increased 7.5% NCT03172494 · Phase 3 · registry result, not featured evidence decreased appetite 14.4% diarrhoea 14.4% lipase increased 12.2% NCT03172494 · Phase 3 · registry result, not featured evidence nausea 37.2% (placebo 2.7%) diarrhea 17.9% (placebo 17.3%) allergic reaction to liraglutide 1.3% (placebo 0%) NCT01234649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 12.6% lipase increased 12% diabetic retinopathy 11.6% NCT03175120 · Phase 3 · registry result, not featured evidence headache 11.5% nasopharyngitis 11.3% diarrhoea 7.7% NCT02501161 · Phase 3 · registry result, not featured evidence nausea 26.2% (placebo 6%) decreased appetite 9.4% (placebo 0%) diarrhoea 9.4% (placebo 3%) NCT02964247 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 38.5% constipation 9.8% diabetic retinopathy 6.2% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 34.4% constipation 13.9% diarrhoea 8.8% NCT02607306 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 20% diabetic retinopathy 16.2% diarrhoea 14.3% NCT02911948 · Phase 3 · registry result, not featured evidence headache 8.6% viral upper respiratory tract infection 7.7% lipase increased 5.7% NCT02773368 · Phase 3 · registry result, not featured evidence nausea 11.1% influenza 7.1% diarrhoea 6.3% NCT02420262 · Phase 3 · registry result, not featured evidence headache 12.5% (placebo 12.5%) asympomatic hyppglycaemia 6.3% (placebo 0%) nausea 6.3% (placebo 0%) NCT01937598 · Phase 3 · registry result, not featured evidence | 1.0 mgt nausea 21.8% (placebo 7.5%) diarrhoea 18% (placebo 11.8%) vomiting 14.8% (placebo 5.1%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 42 more results0.5 mg diarrhoea 17.9% (placebo 11.8%) nausea 17.3% (placebo 7.5%) lipase increased 11.4% (placebo 8%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 1.0 mg nausea 22.3% diarrhoea 11.4% lipase increased 10.1% NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.0 mg weekly nausea 23.8% (placebo 7.8%) diarrhoea 10.8% (placebo 2.3%) headache 6.9% (placebo 6.2%) NCT02054897 · Phase 3 0.5 mg weekly nausea 20.3% (placebo 7.8%) diarrhoea 12.5% (placebo 2.3%) headache 11.7% (placebo 6.2%) NCT02054897 · Phase 3 1.0 mg weekly nausea 16.8% (placebo 4.5%) vomiting 11.5% (placebo 3%) diarrhoea 6.9% (placebo 1.5%) NCT02305381 · Phase 3 0.5 mg weekly nausea 11.4% (placebo 4.5%) lipase increased 9.1% (placebo 3%) nasopharyngitis 8.3% (placebo 10.5%) NCT02305381 · Phase 3 abdominal pain 60% NCT05786521 · Phase 4 · registry result, not featured evidence once weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nausea 18.4% diarrhoea 13.5% vomiting 9.7% NCT05514535 · Phase 3 · registry result, not featured evidence · combination 7.2 mg nausea 29% (placebo 11.8%) diarrhoea 18.2% (placebo 8.8%) vomiting 16.6% (placebo 2.9%) NCT05649137 · Phase 3 · registry result, not featured evidence 1.0 mg covid-19 5.6% (placebo 0%) decreased appetite 5.6% (placebo 0%) diabetic retinopathy 5.6% (placebo 5.7%) NCT04865770 · Phase 3 · registry result, not featured evidence covid-19 7.6% (placebo 5.3%) nausea 5.6% (placebo 0.8%) NCT04560998 · Phase 3 · registry result, not featured evidence covid-19 14.4% diarrhoea 12.1% nausea 11.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nausea 14.8% diarrhoea 7.4% nasopharyngitis 6.5% NCT03689374 · Phase 3 · registry result, not featured evidence 1.0 mg weekly diarrhoea 16.9% nausea 13.4% upper respiratory tract infection 13.1% NCT03061214 · Phase 3 · registry result, not featured evidence 0.5 mg weekly diarrhoea 20.2% upper respiratory tract infection 9.8% lipase increased 7.7% NCT03061214 · Phase 3 · registry result, not featured evidence nausea 22.7% diarrhoea 15.1% vomiting 12.8% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1.0 mg nausea 21.5% diarrhoea 15.6% decreased appetite 10.4% NCT03191396 · Phase 3 · registry result, not featured evidence 1.0 mg weekly nausea 19.3% (placebo 3.3%) diarrhoea 11.3% (placebo 6%) vomiting 9.3% (placebo 2%) NCT03086330 · Phase 3 · registry result, not featured evidence 1.0 mg nausea 21% diarrhoea 13.7% vomiting 10.3% NCT02648204 · Phase 3 · registry result, not featured evidence 0.5 mg nausea 22.3% diarrhoea 14.3% vomiting 10% NCT02648204 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 31.1% nausea 19.1% diarrhoea 15.8% NCT02207374 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 33.9% constipation 18.4% nausea 12.1% NCT02207374 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 17.6% nausea 12.7% constipation 11.8% NCT02254291 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16.5% constipation 14.6% nausea 10.7% NCT02254291 · Phase 3 · registry result, not featured evidence 2.0 mg nausea 21.7% (placebo 15.3%) vomiting 18.3% (placebo 6.8%) diarrhoea 15% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 16.0 mg nausea 37.1% (placebo 15.3%) vomiting 25.8% (placebo 6.8%) diarrhoea 21% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 8.0 mg nausea 41.7% (placebo 15.3%) diarrhoea 33.3% (placebo 11.9%) vomiting 23.3% (placebo 6.8%) NCT05486065 · Phase 2 · registry result, not featured evidence 21.6 mg injection site erythema 10.2% (placebo 0%) injection site reaction 10.2% (placebo 0%) diarrhoea 8.5% (placebo 11.5%) NCT05144984 · Phase 2 · registry result, not featured evidence 2.4 mg + 12.0 mg diarrhoea 14.3% (placebo 11.5%) constipation 9.1% (placebo 1.6%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 2.4 mg nausea 19.5% (placebo 1.6%) diarrhoea 14.3% (placebo 11.5%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 21.6 mg diarrhoea 13% (placebo 11.5%) nausea 13% (placebo 1.6%) covid-19 11.7% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 7.2 mg diarrhoea 21.6% (placebo 11.5%) lipase increased 12.2% (placebo 3.3%) nausea 12.2% (placebo 1.6%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 72 weeks versus 104 weeks.
- eAssessment timepoints differ: 104 weeks versus 26 weeks.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gPopulation comparability has not been reviewed for both studies.
- hAssessment timepoints differ: 52 weeks versus 32 weeks.
- iAssessment timepoints differ: 52 weeks versus 26 weeks.
- jTrial phases differ: Phase 4 versus Phase 3.
- kAssessment timepoints differ: 24 weeks versus 32 weeks.
- lThe reported result categories differ.
- mPopulation context differs: registered conditions differ; age eligibility differs (adolescents and adults versus includes children).
- nAssessment timepoints differ: 72 weeks versus 52 weeks.
- oAssessment timepoints differ: 40 weeks versus 26 weeks.
- pTrial phases differ: Phase 2 versus Phase 3.
- qAssessment timepoints differ: 34 weeks versus 26 weeks.
- rAssessment timepoints differ: 104 weeks versus 84 weeks.
- sPopulation comparability has not been reviewed for 32 of these studies.
- tPopulation comparability has not been reviewed for 43 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Victoza)
show 1 more result
show 3 more results
show 1 more result
show 8 more results
+ 101 further endpoints in the CSV export.
Semaglutide (Ozempic)
show 1 more result
show 4 more results
show 4 more results
show 4 more results
+ 91 further endpoints in the CSV export.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
Liraglutide (Victoza)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: July 2028 · NCT07073053 (registry estimate)
Reported efficacy
Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)
Result source: NCT04560998
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Liraglutide (Victoza) | Semaglutide (Ozempic) |
|---|---|---|
| LDL-C, % change | —Not reported | —Not reported |
| Non-HDL-C, % change | —Not reported | —Not reported |
| ApoB, % change | —Not reported | —Not reported |
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | 13% vs 14.9%−1.9 vs placeboNCT01179048 | —Not reported |
LDL-C, % change
- Liraglutide (Victoza)
- —Not reported
- Semaglutide (Ozempic)
- —Not reported
Non-HDL-C, % change
- Liraglutide (Victoza)
- —Not reported
- Semaglutide (Ozempic)
- —Not reported
ApoB, % change
- Liraglutide (Victoza)
- —Not reported
- Semaglutide (Ozempic)
- —Not reported
Lp(a), % change
- Liraglutide (Victoza)
- —Not reported
- Semaglutide (Ozempic)
- —Not reported
3-point MACE (% with event)
- Liraglutide (Victoza)
- 13% vs 14.9%−1.9 vs placeboNCT01179048
- Semaglutide (Ozempic)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Liraglutide (Victoza): 4 of 5 rows · Semaglutide (Ozempic): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Liraglutide (Victoza) | Semaglutide (Ozempic) |
|---|---|---|
| HbA1c absolute change · percentage points | 6.7% (n=27) vs 6.8% (n=28) placebo @ 26wka,b,c,d NCT04881110 · Phase 4 · registry result, not featured evidence | -0.8% (n=304) vs 0.2% (n=311) placebo @ 52wka,b,c,d NCT04560998 · Phase 3 |
| Dropout rate | 3%e NCT01179048 · Phase 3 show 3 more results0% NCT03260881 · Phase 4 · registry result, not featured evidence 10% NCT04881110 · Phase 4 · registry result, not featured evidence 0% NCT03010683 · Phase na · registry result, not featured evidence | 7.6%e NCT04560998 · Phase 3 |
| Discontinued due to AEs | —e NCT01179048 · Phase 3 show 3 more results— NCT03260881 · Phase 4 · registry result, not featured evidence — NCT04881110 · Phase 4 · registry result, not featured evidence — NCT03010683 · Phase na · registry result, not featured evidence | —e NCT04560998 · Phase 3 |
| Serious AEs | 49.7%e NCT01179048 · Phase 3 show 3 more results0% NCT03260881 · Phase 4 · registry result, not featured evidence 0% NCT04881110 · Phase 4 · registry result, not featured evidence 0% NCT03010683 · Phase na · registry result, not featured evidence | 18.7%e NCT04560998 · Phase 3 |
| Most frequent reported AEs | show 1 more resultabdominal distention 31.6% nausea 31.6% NCT03260881 · Phase 4 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 26 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Liraglutide (Victoza)
Semaglutide (Ozempic)
show 1 more result
show 1 more result
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Victoza)'s landscape · Semaglutide (Ozempic)'s landscape